Citi analyst Yigal Nochomovitz initiated coverage of Lenz Therapeutics with a Buy rating and $34 price target. The analyst called Lenz “strongly poised to disrupt the presbyopia landscape” following positive Phase 3 data and the completion of the reverse merger with Graphite Bio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
